GT Biopharma (GTBP)
NASDAQ:GTBP
Top Page
GT Biopharma
(NASDAQ:GTBP)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.39
▼(-46.58% Downside)
Action:UpgradedDate:03/02/26
The score is primarily weighed down by weak financial performance—no revenue, large ongoing losses, and persistent cash burn that imply continued financing needs. Technicals add pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because a negative P/E reflects unprofitability and no dividend yield is provided.
Positive Factors
Proprietary platform (TriKE/TetraKE)
GT Biopharma’s TriKE/TetraKE NK-cell engager platforms provide a proprietary, platform-style technology that can be applied across hematologic and solid tumors. Platform breadth supports multiple internal candidates, licensing or partnerships, creating durable pipeline optionality beyond one asset.
Negative Factors
No revenue; large recurring losses
The company remains pre-revenue with substantial recurring losses, meaning fundamentals depend entirely on successful R&D outcomes or external deals. This prolongs the path to sustainable cash generation and increases reliance on financing or partnerships to continue operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary platform (TriKE/TetraKE)
GT Biopharma’s TriKE/TetraKE NK-cell engager platforms provide a proprietary, platform-style technology that can be applied across hematologic and solid tumors. Platform breadth supports multiple internal candidates, licensing or partnerships, creating durable pipeline optionality beyond one asset.
Read all positive factors
GT Biopharma (GTBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.90M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth54.62%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,553,892
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.07
Forecast
1Y Price Target
$3.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GT Biopharma Business Overview & Revenue Model
Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology...
How the Company Makes Money
null...
GT Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -34.32M | -13.16M | 5.98M | -20.96M | -57.48M |
| Net Income | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
Balance Sheet | |||||
| Total Assets | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Cash, Cash Equivalents and Short-Term Investments | 6.81M | 3.95M | 13.97M | 16.51M | 31.98M |
| Total Debt | 0.00 | 0.00 | 58.00K | 174.00K | 31.00K |
| Total Liabilities | 2.32M | 5.90M | 6.63M | 5.00M | 10.26M |
| Stockholders Equity | 5.79M | -1.67M | 7.48M | 11.73M | 21.91M |
Cash Flow | |||||
| Free Cash Flow | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Operating Cash Flow | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Investing Cash Flow | 0.00 | 12.89M | -2.01M | 12.14M | -23.04M |
| Financing Cash Flow | 15.78M | 2.98M | 6.27M | -224.00K | 42.32M |
GT Biopharma Technical Analysis
Negative
0.73
Price Trends
0.52
Negative
0.62
Negative
1.07
Negative
Market Momentum
-0.02
Negative
38.83
Neutral
41.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.52, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 38.83 is Neutral, neither overbought nor oversold. The STOCH value of 41.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.
GT Biopharma Risk Analysis
GT Biopharma disclosed 60 risk factors in its most recent earnings report. GT Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GT Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $9.28M | -0.10 | -209.36% | ― | ― | 83.25% | |
44 Neutral | $3.35M | ― | -203.36% | ― | ― | 90.53% | |
43 Neutral | $3.89M | -0.12 | -215.04% | ― | -100.00% | 93.82% | |
42 Neutral | $4.20M | -2.23 | -0.40% | ― | ― | 96.26% | |
41 Neutral | $12.90M | -0.15 | -356.99% | ― | ― | 54.62% |
* Healthcare Sector Average
GTBP
GT Biopharma
0.41
-1.74
-81.02%
TOVX
Theriva Biologics
0.20
-0.90
-81.64%
REVB
Revelation Biosciences
1.13
-30.43
-96.42%
DRMA
Dermata Therapeutics
1.18
-9.62
-89.07%
CERO
CERo Therapeutics Holdings
0.03
-14.57
-99.78%
AZTR
Azitra Inc
0.24
-1.78
-88.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.